CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 30 target
Drug / intervention
Cell therapy for solid tumorsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06196294
NCT06196294Phase 1RecruitingOn TrackUpdated 24mo ago
CompareCT.gov

GPC3/Mesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical Trial

Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jan 9, 2024·Updated Jun 26, 2024

In Brief

A Phase 1 clinical trial evaluating Cell therapy for solid tumors for Pancreas Cancer and 5 related conditions. Currently recruiting, targeting 30 participants across 1 site.

Detailed Summary

The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma, CAR-T Cell Therapy, Solid Tumor, Adult
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20242025202620272028202920302031203220332034203520362037
First PostedJan 9, 2024
Enrollment StartMay 10, 2024
Primary CompletionNov 30, 2030
Study CompletionDec 30, 2036
TodayJul 1, 2026
Enrollment to primary: 6.6 yearsPosted 2.5 years agoPrimary completion in 4.4 years

Interventions

Cell therapy for solid tumorsbiological

Transfer γδT cells into patients for anti-ancer therapy.